Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/15439 |
Resumo: | Introduction: The treatment of diseases caused by enterobacteria is an increasing challenge. This problem results from the inefficiency of antibiotics to fight pathogens or to stimulate phagocytosis of cells of the reticuloendothelial system, mainly against bacteria that install and multiply inside phagocytic cells. Some antibiotics are ineffective at entering cells or have their capacity reduced by the plasma membrane. Thus, the scientific community joins efforts seeking new therapeutic alternatives that overcome these limitations. Liposomes are lipid nanocarriers capable of encapsulating antibiotics, aiming at increasing the specificity of delivery, the concentration of compounds delivered to the site, maintaining the plasma concentration of drugs and protecting the active molecules. Thus, the objective of this review was to describe the main liposomal properties, emphasizing the advantages of using these lipid vesicles to administer antibiotics against infections caused by enterobacteria. Methodology: This is a bibliographic review through searches in national and international electronic databases, selecting articles from 2007 to 2020 using the descriptors: Gram-negative bacteria, bacterial resistance, antimicrobials and nanotechnology. Results: Cationic and furtive liposomes consisting mainly of cholesterol, PEG, phosphatidylcholine and carboxymethyl chitosan encapsulating drugs such as amoxicillin, ciprofloxacin, cloxacillin, vancomycin, azithromycin, amoxicillin, cefepime, gentamicin and cefotaxime have shown antibacterial activity. Liposomes encapsulating drugs such as chloramphenicol, azithromycin, gentamicin and polymyxin B showed greater antibiofilm efficiency compared to enterobacteria when compared to non-encapsulated drugs. Conclusion: The results showed that liposomes have significant therapeutic potential for the treatment of infections caused by enterobacteria. |
id |
UNIFEI_9bc6651961e19da7617b27dfb2c11a13 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/15439 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteriaVentajas de usar antibioticos encapsulados en liposomas para combatir infecciones causadas por enterobactériasVantagens da utilização de antibióticos encapsulados em lipossomas para o combate de infecções causadas por enterobactériasBacterias Gram negativasResistencia bacterianaAntimicrobianosNanotecnología.Gram-negative bactériaBacterial resistanceAntimicrobialsNanotechnology.Bactérias Gram-negativasResistência bacterianaAntimicrobianosNanotecnologia.Introduction: The treatment of diseases caused by enterobacteria is an increasing challenge. This problem results from the inefficiency of antibiotics to fight pathogens or to stimulate phagocytosis of cells of the reticuloendothelial system, mainly against bacteria that install and multiply inside phagocytic cells. Some antibiotics are ineffective at entering cells or have their capacity reduced by the plasma membrane. Thus, the scientific community joins efforts seeking new therapeutic alternatives that overcome these limitations. Liposomes are lipid nanocarriers capable of encapsulating antibiotics, aiming at increasing the specificity of delivery, the concentration of compounds delivered to the site, maintaining the plasma concentration of drugs and protecting the active molecules. Thus, the objective of this review was to describe the main liposomal properties, emphasizing the advantages of using these lipid vesicles to administer antibiotics against infections caused by enterobacteria. Methodology: This is a bibliographic review through searches in national and international electronic databases, selecting articles from 2007 to 2020 using the descriptors: Gram-negative bacteria, bacterial resistance, antimicrobials and nanotechnology. Results: Cationic and furtive liposomes consisting mainly of cholesterol, PEG, phosphatidylcholine and carboxymethyl chitosan encapsulating drugs such as amoxicillin, ciprofloxacin, cloxacillin, vancomycin, azithromycin, amoxicillin, cefepime, gentamicin and cefotaxime have shown antibacterial activity. Liposomes encapsulating drugs such as chloramphenicol, azithromycin, gentamicin and polymyxin B showed greater antibiofilm efficiency compared to enterobacteria when compared to non-encapsulated drugs. Conclusion: The results showed that liposomes have significant therapeutic potential for the treatment of infections caused by enterobacteria.Introducción: El tratamiento de enfermedades causadas por enterobacterias es un desafío cada vez mayor. Este problema se debe a la ineficacia de los antibióticos para combatir patógenos o para estimular la fagocitosis de células del sistema reticuloendotelial, principalmente contra bacterias que se instalan y multiplican dentro de las células fagocíticas. Algunos antibióticos son ineficaces para ingresar a las células o tienen su capacidad reducida por la membrana plasmática. De esta forma, la comunidad científica une esfuerzos en la búsqueda de nuevas alternativas terapéuticas que superen estas limitaciones. Los liposomas son nanoportadores de lípidos capaces de encapsular antibióticos, con el objetivo de aumentar la especificidad de la administración, la concentración de compuestos administrados al sitio, mantener la concentración plasmática de los medicamentos y proteger los principios activos. Así, el objetivo de esta revisión fue describir las principales propiedades liposomales, enfatizando las ventajas de utilizar estas vesículas lipídicas para administrar antibióticos frente a infecciones causadas por enterobacterias. Metodología: Se trata de una revisión bibliográfica mediante búsquedas en bases de datos electrónicas nacionales e internacionales, seleccionando artículos de 2007 a 2020 utilizando los descriptores: Bacterias gramnegativas, Resistencia bacteriana, Antimicrobianos y Nanotecnología. Resultados: Liposomas catiónicos y furtivos constituidos principalmente por fármacos encapsulantes de colesterol, PEG, fosfatidilcolina y carboximetilquitosano como amoxicilina, ciprofloxacina, cloxacilina, vancomicina, azitromicina, amoxicilina, cefepima, gentamicina y cefotaxima. Los liposomas que encapsulan fármacos como cloranfenicol, azitromicina, gentamicina y polimixina B mostraron una mayor eficacia antibiofilm en comparación con las enterobacterias en comparación con los fármacos no encapsulados. Conclusión: Los resultados mostraron que los liposomas tienen un potencial terapéutico significativo para el tratamiento de infecciones causadas por enterobacterias.Introdução: O tratamento de doenças causadas por enterobactérias é um desafio cada vez maior. Esse problema resulta na ineficiência dos antibióticos combaterem os patógenos ou estimularem a fagocitose de células do sistema reticuloendotelial, principalmente contra bactérias que se instalam e se multiplicam no interior de células fagocíticas. Alguns antibióticos são ineficazes em adentrar as células ou tem sua capacidade reduzida pela membrana plasmática. Assim, a comunidade científica reúne esforços buscando novas alternativas terapêuticas que ultrapassem essas limitações. Os lipossomas são nanocarreadores lipídicos capazes de encapsular antibióticos, visando o aumento na especificidade da entrega, a concentração de compostos entregues ao local, manter a concentração plasmática dos fármacos e proteger os princípios ativos. Assim, o objetivo dessa revisão foi descrever as principais propriedades lipossomais, enfatizando as vantagens de utilizar essas vesículas lipídicas para administração de antibióticos frente a infecções causadas por enterobactérias. Metodologia: Trata-se de uma revisão bibliográfica através de buscas nas bases eletrônicas nacionais e internacionais selecionando artigos de 2007 a 2020 utilizando os descritores: Bactérias gram-negativas, Resistência bacteriana, Antimicrobianos e Nanotecnologia. Resultados: Lipossomas catiônicos e furtivos constituídos principalmente por colesterol, PEG, fosfatidilcolina e carboximetilquitosana encapsulando fármacos como amoxicilina, ciprofloxacina, cloxacilina, vancomicina, azitromicina, amoxicilina, cefepime, gentamicina e cefotaxime demonstraram atividade antibacteriana. Lipossomas encapsulando fármacos como cloranfenicol, azitromicina, gentamicina e polimixina B apresentaram maior eficiência antibiofilme frente a enterobactérias quando comparados aos fármacos não encapsulado. Conclusão: Os resultados mostraram que os lipossomas apresentam potencial terapêutico significativo para o tratamento de infecções causadas por enterobactérias.Research, Society and Development2021-05-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1543910.33448/rsd-v10i6.15439Research, Society and Development; Vol. 10 No. 6; e15010615439Research, Society and Development; Vol. 10 Núm. 6; e15010615439Research, Society and Development; v. 10 n. 6; e150106154392525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/15439/13968Copyright (c) 2021 Júlio Eduardo Barbosa da Silva; Jaqueline Barbosa de Souza; Daniel Charles dos Santos Macêdo; Luís André de Almeida Campos; Isabella Macário Ferro Cavalcantihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Júlio Eduardo Barbosa da Souza, Jaqueline Barbosa de Macêdo, Daniel Charles dos Santos Campos, Luís André de Almeida Cavalcanti, Isabella Macário Ferro2021-06-10T22:51:46Zoai:ojs.pkp.sfu.ca:article/15439Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:36:15.788892Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria Ventajas de usar antibioticos encapsulados en liposomas para combatir infecciones causadas por enterobactérias Vantagens da utilização de antibióticos encapsulados em lipossomas para o combate de infecções causadas por enterobactérias |
title |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
spellingShingle |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria Silva, Júlio Eduardo Barbosa da Bacterias Gram negativas Resistencia bacteriana Antimicrobianos Nanotecnología. Gram-negative bactéria Bacterial resistance Antimicrobials Nanotechnology. Bactérias Gram-negativas Resistência bacteriana Antimicrobianos Nanotecnologia. |
title_short |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
title_full |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
title_fullStr |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
title_full_unstemmed |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
title_sort |
Advantages of using liposome-encapsulated antibiotics to fight infections caused by enterobacteria |
author |
Silva, Júlio Eduardo Barbosa da |
author_facet |
Silva, Júlio Eduardo Barbosa da Souza, Jaqueline Barbosa de Macêdo, Daniel Charles dos Santos Campos, Luís André de Almeida Cavalcanti, Isabella Macário Ferro |
author_role |
author |
author2 |
Souza, Jaqueline Barbosa de Macêdo, Daniel Charles dos Santos Campos, Luís André de Almeida Cavalcanti, Isabella Macário Ferro |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Silva, Júlio Eduardo Barbosa da Souza, Jaqueline Barbosa de Macêdo, Daniel Charles dos Santos Campos, Luís André de Almeida Cavalcanti, Isabella Macário Ferro |
dc.subject.por.fl_str_mv |
Bacterias Gram negativas Resistencia bacteriana Antimicrobianos Nanotecnología. Gram-negative bactéria Bacterial resistance Antimicrobials Nanotechnology. Bactérias Gram-negativas Resistência bacteriana Antimicrobianos Nanotecnologia. |
topic |
Bacterias Gram negativas Resistencia bacteriana Antimicrobianos Nanotecnología. Gram-negative bactéria Bacterial resistance Antimicrobials Nanotechnology. Bactérias Gram-negativas Resistência bacteriana Antimicrobianos Nanotecnologia. |
description |
Introduction: The treatment of diseases caused by enterobacteria is an increasing challenge. This problem results from the inefficiency of antibiotics to fight pathogens or to stimulate phagocytosis of cells of the reticuloendothelial system, mainly against bacteria that install and multiply inside phagocytic cells. Some antibiotics are ineffective at entering cells or have their capacity reduced by the plasma membrane. Thus, the scientific community joins efforts seeking new therapeutic alternatives that overcome these limitations. Liposomes are lipid nanocarriers capable of encapsulating antibiotics, aiming at increasing the specificity of delivery, the concentration of compounds delivered to the site, maintaining the plasma concentration of drugs and protecting the active molecules. Thus, the objective of this review was to describe the main liposomal properties, emphasizing the advantages of using these lipid vesicles to administer antibiotics against infections caused by enterobacteria. Methodology: This is a bibliographic review through searches in national and international electronic databases, selecting articles from 2007 to 2020 using the descriptors: Gram-negative bacteria, bacterial resistance, antimicrobials and nanotechnology. Results: Cationic and furtive liposomes consisting mainly of cholesterol, PEG, phosphatidylcholine and carboxymethyl chitosan encapsulating drugs such as amoxicillin, ciprofloxacin, cloxacillin, vancomycin, azithromycin, amoxicillin, cefepime, gentamicin and cefotaxime have shown antibacterial activity. Liposomes encapsulating drugs such as chloramphenicol, azithromycin, gentamicin and polymyxin B showed greater antibiofilm efficiency compared to enterobacteria when compared to non-encapsulated drugs. Conclusion: The results showed that liposomes have significant therapeutic potential for the treatment of infections caused by enterobacteria. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-05-26 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/15439 10.33448/rsd-v10i6.15439 |
url |
https://rsdjournal.org/index.php/rsd/article/view/15439 |
identifier_str_mv |
10.33448/rsd-v10i6.15439 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/15439/13968 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 6; e15010615439 Research, Society and Development; Vol. 10 Núm. 6; e15010615439 Research, Society and Development; v. 10 n. 6; e15010615439 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052677562040320 |